Endoscopic-assisted orbital exenteration: Technical feasibility and surgical results from a single-center consecutive series

Author(s):  
Mario Turri-Zanoni ◽  
Alberto Daniele Arosio ◽  
Edoardo Agosti ◽  
Paolo Battaglia ◽  
Mario Cherubino ◽  
...  
2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 6562-6562
Author(s):  
Anna B. Halpern ◽  
Rangesh Kunnavakkum ◽  
Loren Joseph ◽  
Wendy Stock ◽  
Olatoyosi Odenike ◽  
...  

6562 Background: Activating mutations of the fms-like tyrosine kinase-3 (FLT3) gene are common in AML. Depending upon the allele mutation fraction, these mutations have been associated with poor outcomes in prospective multi-center trials. Methods: We studied a consecutive series of adults with FLT3-mutated leukemia at our institution since we began testing in 2006 through Sept 2011. Clinical characteristics and patient (pt) outcomes were extracted through a retrospective chart review and analyzed using logistic regression and Cox proportional hazard models. Results: We identified 73 pts with a FLT3 mutation (71 with AML and 2 with myelodysplasia with <20% blasts). 62 (85%) presented to our institution at initial diagnosis; 11 (15%) were diagnosed elsewhere and seen by us only at relapse. 44 (60%) were men and 51 (70%) were white. Median age was 62 yrs (range, 19-90); 48% were <60 yrs old. 63 (86%) had an internal tandem duplication (ITD) mutation, 9 (12%) had the D835 point mutation (TKD), and 1 had both. An NPM1 mutation was also present in 26 (36%). Median white blood cell count at diagnosis was 53 x 103/µL (range, 0.8 - 466). 34 (47%) had monocytic morphology (M4 or M5). 8 (11%) pts had favorable karyotypes; 50 (68%) had normal karyotypes; 13 (18%) had unfavorable karyotypes. 58 (79%) received standard induction therapy (anthracycline + cytarabine for most; ATRA + arsenic trioxide for 3 with APL); 46/58 (79%) achieved a complete remission (CR). Including the 15 pts who received only low intensity therapies, 40/64 (63%) with an ITD and 6/9 (67%) with a TKD mutation achieved CR. 31 (42%) pts received an allogeneic transplant, 21 in first CR (CR1) and 10 after relapse. Median overall survival (OS) for the whole group was 417 days (95% CI: 291-780); it was 684 days for those diagnosed at our institution and 285 days for those seen only after relapse. Median disease-free survival (DFS) in CR1 was 417 days. Median OS for pts transplanted in CR1 was 1262 days from initial diagnosis and 416 days for those transplanted after relapse. DFS did not differ with or without a transplant (median, 526 vs 305 days; p=.64). Conclusions: FLT3-mutated AML is heterogeneous. Our single center experience is similar to that reported from multi-center trials.


2020 ◽  
Vol 37 (1) ◽  
pp. 51-54
Author(s):  
Anuradha Jayaprakasam ◽  
Kaveh Vahdani ◽  
Geoffrey E. Rose ◽  
George M. Saleh ◽  
Badrul Hussain ◽  
...  

2020 ◽  
Vol 92 (1) ◽  
pp. 25-29
Author(s):  
Omer Bayrak ◽  
Sakip Erturhan ◽  
Ilker Seckiner ◽  
Mehmet Ozturk ◽  
Haluk Sen ◽  
...  

Objective: To compare the surgical results, complications, and satisfaction levels of patients who underwent malleable penile prosthesis implantation (M-PPI) and Ambicor penile prosthesis implantation (A-PPI). Material and methods: One hundred forty two patients who underwent penile prosthesis implantation [M-PPI (Promedon- Tube®, Cordoba, Argentina): 81, and A-PPI (American Medical Systems, Minnesota, USA): 61] between 2013-2018 were evaluated retrospectively. Patients’ age, body mass index, smoking history, etiological factors, modified “Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire” scores, shortening of the penis, and complications were recorded. Results: The patients who performed A-PPI implantation were younger (56.27 ± 10.81 vs. 51.47 ± 11.79, p = 0.009). The EDITS scores of 31(38.2%) patients who underwent M-PPI and 44 (72.4%) patients who underwent A-PPI were available. It was observed that the scores on the following questions were statistical significantly higher in the A-PPI group: “Overall, are you satisfied with your penile prosthesis?, How much of your expectations did penile prosthesis meet?, How often do you use your penile prosthesis?” (p = 0.05, p = 0.048, p = 0.038). No difference was observed between the groups in terms of the scores on the other three questions (p = 0.447, p = 0.326, p = 0.365). A 61.3% of patients in MPPI (19/31) group, and 56.8% of patients in A-PPI (25/44) group stated penile shortening (p = 0.417). Mean shortening was reported as 2.1 ± 0.45 cm, and 2.12 ± 0.52 cm, in M-PPI and A-PPI groups, respectively (p = 0.90). Conclusion:It is remarkable that the patients who underwent A-PPI experienced higher satisfaction with their prosthesis. Even though it has not been evidenced in the current literature data, patients who have had either M-PPI or A-PPI should be informed about the risk of penile shortening.


2020 ◽  
Vol 45 (12) ◽  
pp. 4150-4159
Author(s):  
Joan C. Vilanova ◽  
Anna Pérez de Tudela ◽  
Josep Puig ◽  
Martijn Hoogenboom ◽  
Joaquim Barceló ◽  
...  

Author(s):  
William Uribe ◽  
Edgardo González ◽  
Adrian Baranchuk ◽  
Ana Milena Herrera ◽  
Eduardo Medina ◽  
...  

2017 ◽  
Vol 99 (7) ◽  
pp. 545-549 ◽  
Author(s):  
H Okamoto ◽  
K Miura ◽  
J Itakura ◽  
H Fujii

IntroductionCholelithiasis usually can be managed successfully by endoscopic sphincterotomy. Choledochoduodenostomy (CDD) is one of the surgical treatment options but its acceptance remains debated because of the risk of reflux cholangitis and sump syndrome. The aim of this study was to assess the current features and outcomes of patient undergoing CDD.Patients and methodsWe retrospectively analysed the surgical results of consecutive 130 patients treated by CDD between 1991 and 2013 and excluded five cases with a malignant disorder. Indications for surgery included endoscopic management where stones were difficult or failed to pass and primary common bile duct stones with choledochal dilatation. Incidences of reflux cholangitis, stone recurrence, pancreatitis or sump syndrome were investigated and the data between end-to-side and side-to-side CDD were compared.ResultsReflux cholangitis and stone recurrence was 1.6% (2/125) and 0% (0/125) of cases by CDD. There is no therapeutic-related pancreatitis in CDD. Sump syndrome was not also observed in side-to-side CDD.ConclusionsThis study is a first comparative study between end-to-side and side-to-side CDD. The surgical outcomes for CDD treatment of choledocholithiasis were acceptable. The incidence of reflux cholangitis, stone recurrence, pancreatitis and sump syndrome was very low.


Sign in / Sign up

Export Citation Format

Share Document